Who Owns Lung Nodule Follow Up in Health Systems and Why That Matters

Lung nodules are detected every day across U.S. health systems. What remains unclear in many organizations is who owns what happens next.

Radiologists identify nodules. Primary care physicians receive reports. Pulmonologists manage high-risk cases. Nurse navigators coordinate follow up. Administrators oversee quality metrics. Yet when follow up fails, responsibility is often diffuse.

This lack of ownership is one of the most common reasons lung nodules do not receive timely follow up. For radiology leaders, IPN program leads, and hospital executives, clarifying ownership is not an operational detail. It is a patient safety issue.

Incidental pulmonary nodules are common. Studies estimate that up to 30 percent of chest CT scans identify at least one pulmonary nodule. With more than 90 million CT scans performed annually in the United States, this translates to well over a million new nodules each year.

Despite clear clinical guidelines, follow up remains inconsistent. Multiple studies have shown that 30 to 50 percent of patients with incidentally detected lung nodules do not receive guideline-recommended follow up imaging. In some systems, the rate is higher when nodules are detected outside formal lung cancer screening programs.

Missed follow up has real consequences. Research has shown that nodules lost to follow up are associated with delayed lung cancer diagnosis, more advanced stage at diagnosis, and worse survival outcomes.

The question health systems must ask is not whether nodules are being detected. It is whether someone is clearly accountable for ensuring follow up occurs.

Ownership of lung nodule follow up often fails because responsibility is spread across multiple roles without a defined handoff.

Radiologists detect nodules and document them in reports. Their primary responsibility ends with accurate interpretation and communication of findings. In many organizations, radiologists are not expected to track patients longitudinally.

Primary care physicians receive the report but may not see it in a timely manner. They manage many competing priorities and may not be aware of guideline-specific follow up recommendations for nodules.

Pulmonologists typically become involved only after referral. If a referral is not generated, the patient may never reach specialty care.

Nurse navigators are often tasked with coordinating follow up, but they are rarely empowered with formal ownership. In many health systems, navigators operate without dedicated infrastructure or authority.

Hospital leadership may assume that existing processes are sufficient, particularly if no adverse events have surfaced recently.

The result is a system where everyone is involved, but no one clearly owns the outcome.

Radiology Perspective: Detection Is Not Closure

From a radiology standpoint, the problem is not detection. It is transition.

Radiology reports often include descriptive findings but lack standardized follow up recommendations. Studies have found that fewer than half of radiology reports include explicit follow up guidance for pulmonary nodules.

Even when recommendations are included, they may not be clearly actionable. Free text reporting can obscure key details such as nodule size, risk category, and suggested interval.

Radiologists are increasingly aware that detection without follow up creates downstream risk. However, radiology departments alone cannot own longitudinal care.

What radiology can own is consistency. Structured reporting, standardized language, and clear identification of actionable nodules reduce ambiguity. Radiology also plays a critical role in enabling IPN programs by ensuring nodules are reliably flagged.

Ownership begins with clarity. Radiology sets the foundation, but it cannot carry follow up alone.

IPN Program Leads: Ownership Requires Authority

Incidental Pulmonary Nodule programs exist to solve the ownership gap. When designed well, an IPN program creates a single point of accountability for nodule follow up.

Successful IPN programs share common features:

Published case studies from large U.S. health systems show that IPN programs can significantly improve follow up adherence and reduce diagnostic delays. Programs that assign clear ownership report higher completion rates of recommended imaging and earlier stage lung cancer diagnoses.

However, IPN programs fail when ownership is nominal rather than real. Program leads must have authority to act. This includes the ability to contact patients, order follow up imaging under protocol, and escalate cases when delays occur.

Without this authority, IPN programs become passive registries rather than active safety nets.

The CXO View: Ownership Is a Governance Decision

For hospital executives, lung nodule follow up is often invisible until something goes wrong.

Missed nodules rarely trigger immediate financial penalties. They surface later as advanced cancers, malpractice claims, or quality reviews. By then, root cause analysis often reveals fragmented responsibility.

From a governance perspective, ownership of lung nodule follow up should be treated like other patient safety processes. Just as hospitals define ownership for abnormal lab results or critical findings, they must define ownership for nodules.

Health systems that have addressed this proactively report improved audit readiness and reduced risk exposure. Leadership support is consistently cited as a key factor in IPN program success.

Ownership is not about adding bureaucracy. It is about preventing avoidable harm.

Some organizations attempt shared ownership models, where radiology, primary care, and pulmonology each carry partial responsibility. In practice, this often fails.

Shared ownership without clear accountability leads to diffusion of responsibility. Each team assumes someone else is managing follow up.

Research on diagnostic safety consistently shows that ambiguous responsibility is a major contributor to missed diagnoses. Lung nodules are a textbook example.

Clear ownership does not exclude collaboration. It simply defines who is responsible for ensuring the process completes.

Technology Supports Ownership, It Does Not Define It

Technology alone cannot solve the ownership problem. However, it can support accountable workflows.

Tools that reliably identify nodules, standardize measurements, and provide longitudinal visibility enable IPN programs to function at scale. They reduce dependence on manual review and improve consistency.

<a href="https://www.qure.ai/us">Qure.ai</a> provides FDA-cleared AI tools that support this foundation.

These tools do not assign ownership. They support teams that have already made an ownership decision. By improving detection consistency and measurement reliability, they enable IPN programs and radiology teams to work from objective data.

For CXOs, this distinction matters. Technology should reinforce governance decisions, not substitute for them.

Health systems that successfully manage lung nodules typically answer three questions clearly:

The most effective models place ownership within a formal IPN program, supported by radiology and pulmonary services, with executive oversight.

Nurse navigators often execute the work, but ownership must sit at the program level, not with individuals.

Clear ownership improves outcomes in measurable ways.

It reduces missed follow ups by ensuring no nodule is left unmanaged. It shortens time to diagnosis by preventing delays. It improves patient trust by providing clear communication and continuity.

From a system perspective, it reduces risk. Health systems with formal IPN programs report better documentation, improved compliance with guidelines, and fewer adverse events related to delayed diagnosis.

For radiology leaders, it ensures that findings lead to action. For IPN leads, it provides authority to manage care. For CXOs, it aligns patient safety with operational accountability.

Lung nodules will continue to increase as imaging volumes grow. Detection will improve. Without ownership, follow up will continue to fail.

The question is not whether health systems can afford to define ownership. It is whether they can afford not to.

Clear ownership of lung nodule follow up is a foundational step toward reliable early lung cancer diagnosis.

To learn more about FDA-cleared tools that support lung nodule detection and longitudinal assessment within IPN and radiology workflows, reach out to us on partner@qure.ai.&nbsp;

&nbsp; 1. Mazzone PJ, Lam L. Evaluating the Patient With a Pulmonary Nodule: A Review -&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/35040882/">JAMA</a>

2- Smith-Bindman R, Chu PW, Azman Firdaus H, et al. Projected Lifetime Cancer Risks From Current Computed Tomography Imaging -&nbsp; <a href="https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2832778">JAMA</a>

3.&nbsp; Kattih Z, Moore JA, Wilson B, Gajjala S, Schwartz J, Kushner J, Zajac S, Mahajan A, Leung T, Makkar P. - <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12019827/">Rate of Incidental Lung Nodule Follow-Up: A Cohort Study Evaluating Adherence to Guideline Recommendations</a>

large_blog_thumbnail 1.webp

medium_blog_thumbnail 1.webp

small_blog_thumbnail 1.webp

thumbnail_blog_thumbnail 1.webp

Who Owns Lung Nodule Follow Up.webp

What Nurse Navigators Wish Health Systems Understood About Lung Nodule Follow Ups

Lung cancer remains the deadliest cancer in the United States. In 2022, 218,893 new lung cancers were reported and 131,584 people died from lung cancer in the U.S.¹

Fewer than 1 in 3 cases is detected at an early, localized stage². Most lung cancers are found only after they have spread, when 5-year survival is about 9%. Nurse navigators know that catching cancer early, often through lung nodule follow up, is vital to turning the tide. Each pulmonary nodule flagged on an X-ray or CT scan represents a critical moment: the chance to diagnose lung cancer when cure is still possible. But in practice, many nodules fall through the cracks. As one review found, almost 50% of patients with incidental lung nodules never had follow-up scheduled³. To improve lung cancer early diagnosis, health systems must address the real-world challenges of nodule tracking.

Nurse navigators shoulder a heavy burden in lung nodule management. They coordinate care for patients who often have multiple tests and specialists, and they must ensure that every suspicious finding leads to the right next step. Key pain points include:

These challenges leave navigators frustrated.

Beyond individual workloads, systemic issues contribute to missed follow-ups. Health systems often lack an integrated lung nodule tracking software or workflow that closes the loop. Key gaps include:

These system gaps mean that the burden of follow-up often falls unfairly on navigators and patients. Navigators frequently wish for a formal incidental pulmonary nodule (IPN) program - a coordinated process (often with software support) to capture every newly reported nodule and manage its course systematically.

Nurse navigators emphasize that follow-up is a high-stakes juncture. This is the point where potential cancers are caught – or lost. Key reasons why missed follow-up is so dangerous:

In short, the follow-up phase is a critical safeguard. When it fails, the system fails the patient. Nurse navigators know this well and point out that robust follow-up is central to the whole goal of lung cancer early diagnosis.

What Nurse Navigators Need from Health Systems

Given these realities, nurse navigators have clear needs for their health systems:

In summary, nurse navigators call for a close-loop program – often called an IPN (incidental pulmonary nodule) program – that ensures every lung nodule is identified, tracked, and resolved. They advocate for tools that reduce manual burden and keep patients from slipping through cracks. As one navigation report concluded, “the nurse navigators noted improved efficiency and reporting” once such systems were in place.

Artificial intelligence can play a key role in supporting navigators’ work. For example, Qure.ai’s Lung Cancer Suite is an FDA-cleared software suite designed to catch nodules early and track them over time. It includes two main tools:

Both tools are FDA-cleared and built for real-world workflows. They integrate into the PACS/RIS so that AI overlay and measurements appear in the routine reading workflow. This preserves physician control while enhancing detection. In effect, Qure.ai provides lung nodule tracking software capabilities: it automates the spotting and measuring of nodules, making sure nothing is missed. The suite is specifically designed to support evidence-based follow-up – for instance, by providing exact growth rates and alerts – which aligns with navigators’ goal of reliable, standardized tracking.

Importantly, these AI tools address specific navigator needs. By ensuring that virtually all nodules are identified (on X-ray or CT), Qure.ai helps make an IPN program feasible. Having a nodule’s history and growth quantified also empowers the care team to apply guidelines confidently. While nurse navigators focus on patient communication and scheduling, AI aids the radiology side to deliver clean data. Together, this allows more efficient management: navigators only spend time on nodules that truly need intervention.

For health systems seeking to improve lung nodule follow-up, these tools are no magic bullet - they still require a coordinated program. But they are cleared and proven components that strengthen the workflow.

Learn more about <a href="https://www.qure.ai/us">Qure.ai’s</a> lung cancer AI solutions by&nbsp;reaching out to us on partner@qure.ai.&nbsp;

large_blog_thumbnail (1).webp

medium_blog_thumbnail (1).webp

small_blog_thumbnail (1).webp

thumbnail_blog_thumbnail (1).webp

What Nurse Navigators Need.webp

Lung Nodule Tracking Software: How Nurse Navigators Prevent Missed Follow Ups

Lung nodules are common. Missed follow ups are also common. Nurse navigators sit at the intersection of both.

Every year in the United States, millions of chest X-rays and CT scans identify pulmonary nodules. Most are benign, but a small percentage represent early lung cancer. The difference between a benign outcome and a late-stage diagnosis often comes down to one thing: whether the nodule was tracked and followed on time.

This is where lung nodule tracking software has become increasingly important. For nurse navigators, it is not about technology adoption. It is about preventing silent failure.

Why Lung Nodule Follow Up Fails Without Tracking

Studies consistently show that follow up for pulmonary nodules is unreliable when left to manual processes.

Published reviews report that 30 to 50 percent of patients with incidentally detected lung nodules do not receive guideline-recommended follow up imaging. In some health systems, the rate of missed follow up is even higher for nodules found outside formal lung cancer screening programs.

The reasons are structural, not individual.

Radiology reports are read. Findings are documented. But responsibility for follow up is often unclear. A nodule may be seen in the emergency department, on inpatient imaging, or during workup for an unrelated complaint. Once the patient leaves that encounter, the nodule can disappear into the chart.

Nurse navigators are frequently asked to close this gap, but without proper tools, the work becomes fragile.

The Reality of Manual Lung Nodule Tracking

In many hospitals, lung nodule tracking still relies on spreadsheets, email reminders, or shared folders. Nurse navigators manually review reports, log patient details, calculate follow up intervals, and remind providers to order repeat imaging.

This approach introduces risk at every step.

Manual tracking depends on someone noticing the nodule, entering it correctly, and remembering to act at the right time. When patient volumes rise or staff change roles, the system breaks.

Research on diagnostic safety has shown that abnormal imaging results are one of the most common sources of missed or delayed diagnoses, particularly when follow up depends on manual handoffs. Lung nodules are a prime example.

For nurse navigators, this creates constant exposure to blame. When a cancer is diagnosed late, the question becomes why no one followed the earlier finding.

Why Nurse Navigators Rely on Tracking Software

Lung nodule tracking software addresses a simple problem: memory does not scale.

Tracking systems create a structured way to ensure that nodules move from detection to resolution. For nurse navigators, this changes the job from reactive to controlled.

A reliable tracking system typically supports several critical functions:

These functions directly support how nurse navigators are measured. Fewer missed follow ups. Shorter delays. Clear documentation.

Detection Alone Does Not Prevent Missed Follow Ups

It is important to separate detection from tracking.

Radiology AI and improved reporting can increase detection of lung nodules. But detection alone does not ensure follow up. In fact, increased detection without tracking can increase workload without improving outcomes.

Studies have shown that when more incidental nodules are detected, follow up adherence can actually decline unless there is a system in place to manage them. Nurse navigators often see this firsthand. More findings without better coordination simply create more risk.

This is why tracking software must focus on closure, not alerts.

How Lung Nodule Tracking Software Supports Daily Navigation Work

When implemented well, lung nodule tracking software changes how nurse navigators work day to day.

First, it reduces dependence on individual vigilance. Instead of relying on someone to remember a nodule, the system maintains the list.

Second, it standardizes follow up intervals. Guidelines such as Fleischner Society recommendations vary by nodule size, appearance, and patient risk. Software can help ensure that follow up timing aligns with these standards.

Third, it creates accountability. When a follow up is overdue, it is visible. When a patient completes imaging, it is documented. This transparency protects both patients and staff.

Health systems that have implemented structured lung nodule programs report meaningful improvements. Published case studies show significant increases in completed follow up imaging, reductions in diagnostic delay, and improved audit readiness once tracking systems are in place.

The Role of Nurse Navigators in Preventing Missed Follow Ups

Even with software, nurse navigators remain central to lung nodule care.

Tracking systems do not replace clinical judgment. They support it.

Nurse navigators interpret tracking lists, prioritize high-risk nodules, coordinate with pulmonology and oncology, and communicate with patients. Software reduces clerical load so that navigators can focus on decision making and patient support.

In programs where navigators use structured tracking tools, reports show improved efficiency. Navigators spend less time searching for information and more time managing care transitions.

Importantly, these systems also support patient trust. When patients receive timely reminders and clear explanations, anxiety decreases. Follow up completion improves.

Any lung nodule tracking approach must remain clinically sound and regulatory compliant.

Software should support, not override, physician decision making. Recommendations must align with established guidelines. Documentation must be auditable.

From a regulatory standpoint, tools used in detection and measurement must be appropriately cleared for clinical use. Overstated claims or automated decision making without oversight introduce risk.

Nurse navigators are often the first to raise concerns when tools promise more than they can safely deliver.

Where Qure.ai Fits Into Lung Nodule Tracking

Qure.ai provides FDA-cleared AI tools that support lung nodule detection and longitudinal assessment, which are foundational inputs for effective tracking programs.

The <a href="https://www.qure.ai/us">Qure.ai</a> Lung Cancer Detection and Quantification Suite includes:

These tools do not manage patient follow up directly. Instead, they strengthen the reliability of detection and measurement, which are critical inputs for nurse navigators and lung programs.

By improving consistency in identifying and measuring nodules, Qure.ai supports care teams in building tracking workflows that are based on objective data rather than subjective estimates.

Importantly, the tools preserve physician control and are designed to fit within existing radiology workflows.

For nurse navigators, lung nodule tracking software is not about efficiency alone. It is about reducing the risk of missed diagnoses.

Every missed follow up represents a patient who may return later with advanced disease. Tracking systems help ensure that early findings lead to timely action.

As lung cancer screening expands and incidental findings continue to rise, the volume of nodules will only increase. Without scalable tracking, manual processes will continue to fail.

Health systems that invest in structured tracking programs place nurse navigators in a position to succeed. They move from chasing gaps to managing care with confidence.

Moving Toward Reliable Lung Nodule Follow Up

Preventing missed lung nodule follow ups requires more than awareness. It requires systems that support closure.

For nurse navigators, lung nodule tracking software provides the structure needed to manage growing complexity while protecting patients and teams.

Detection, measurement, tracking, and coordination must work together. When they do, early lung cancer diagnosis becomes more reliable.

To learn more about how FDA-cleared AI tools can support lung nodule detection and longitudinal assessment within lung programs reach out to us on partner@qure.ai.&nbsp;&nbsp;

Kattih Z, Moore JA, Wilson B, Gajjala S, Schwartz J, Kushner J, Zajac S, Mahajan A, Leung T, Makkar P. - <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12019827/">Rate of Incidental Lung Nodule Follow-Up: A Cohort Study Evaluating Adherence to Guideline Recommendations&nbsp;</a>

large_blog_thumbnail_1x.webp

medium_blog_thumbnail_1x.webp

small_blog_thumbnail_1x.webp

thumbnail_blog_thumbnail_1x.webp

Lung Nodule Tracking Software.webp

How Lung Nodule Tracking Software Supports Nurse Navigators

Are AI-Enabled Biomarkers Shaping the Future of Early Cancer Diagnosis?

Cancer care is undergoing a fundamental shift. For decades, oncology relied on population averages, standardized protocols, and retrospective indicators to guide treatment. While this approach delivered scale, it often failed to account for individual risk, disease biology, and variability in outcomes. Today, precision oncology is redefining this paradigm placing the right patient, at the right time, on the right treatment pathway. At the center of this transformation lies a powerful enabler: AI-enabled biomarkers, which are increasingly enabling incidental detection &amp; stage shift in cancer care.

Precision oncology moves beyond a one-size-fits-all model toward individualized decision-making informed by data, biology, and risk. It enables care to move upstream, allowing clinicians to intervene with precision by aligning diagnostics, surveillance, and therapy to patient specific risk profiles.

This shift is driven by a simple but critical insight: timing matters. Identifying which patients need immediate escalation versus those who can be safely monitored directly impacts outcomes, resource utilization, and patient experience. Risk stratification is shaping treatment readiness, and it increasingly begins earlier than ever before in the care pathway, frequently triggered by incidental signals on routine imaging, creating opportunities for earlier diagnosis and downstream stage shift.

AI-enabled biomarkers represent a new class of clinical insight. Rather than relying on a single molecular signal, these biomarkers leverage machine learning to extract complex patterns from routine clinical data such as medical images. By analyzing thousands of subtle features simultaneously, AI brings scale, consistency, and earlier insights into incidental cancer detection risk and treatment readiness.

AI Biomarkers in Early Risk Stratification

One of the most significant shifts enabled by AI is that biomarkers are moving upstream. Risk stratification no longer begins after diagnosis; it increasingly starts at the point of first clinical contact or initial imaging.

This upstream approach has profound clinical and operational value. Earlier identification of high-risk patients enables faster diagnostic escalation, more efficient referral pathways, reduced delays in treatment initiation, and better allocation of specialist and imaging resources, all of which contribute to stage shift and early diagnosis.

Case Example: Qure’s AI Derived Imaging Biomarkers

A clear illustration of this shift is the Lung Nodule Malignancy Score (LNMS) developed by <a href="https://www.qure.ai/us">Qure.ai</a>. LNMS is a patented AI-derived biomarker designed to assess malignancy risk in lung nodules on <a href="https://www.qure.ai/product/qxr">chest X-rays</a>.

By analyzing radiographic patterns , the tool distinguishes higher-risk nodules from lower-risk ones early in the pathway.

The impact is tangible. Clinicians gain immediate insight into which patients warrant accelerated diagnostics and which can be monitored safely. This enables earlier diagnostic decisions, improved patient prioritization, and stronger precision oncology workflow without changing existing imaging practices, thereby increasing likelihood of detecting cancer at an earlier stage.

The true value of AI derived imaging biomarkers lies behind the pathway. Insights generated by AI do not exist in isolation; they inform downstream clinical actions.

Risk stratification influences decisions such as escalation of imaging or biopsy, urgency of specialist referrals, and treatment sequencing. By embedding AI-derived risk insights into routine workflows, care teams can move from reactive decision-making to proactive, data-informed action thereby enabling early diagnosis.

Broader Implications for Oncology and Clinical Trials

Beyond clinical care, AI derived imaging biomarkers are reshaping oncology research and drug development. By improving patient selection and eligibility matching, AI-enabled biomarkers can accelerate clinical trial enrollment, and improve outcome predictability.

AI derived imaging biomarkers are no longer experimental concepts they are becoming foundational infrastructure for modern cancer care. By moving risk stratification upstream, informing treatment readiness, and translating insight into action, they strengthen every layer of the precision oncology ecosystem.

As these tools mature, they will continue to complement and amplify precision medicine driving earlier intervention, smarter pathways, and better outcomes for patients worldwide.

large_blog_thumbnail.webp

medium_blog_thumbnail.webp

small_blog_thumbnail.webp

thumbnail_blog_thumbnail.webp

blog_thumbnail.webp

How AI-Enabled Biomarkers Improve Early Cancer Diagnosis.

Working at Qure.ai, much of my reading revolves around healthcare, the devastating impact of diseases like tuberculosis (TB), and the transformative role AI can play in addressing these challenges. But <a href="https://www.cdc.gov/tb/stories/mary.html" target="_blank">a story</a> I came across recently stood out as a poignant reminder of why this work matters and the driving force behind everything I strive to articulate.&nbsp;

Seventeen-month-old Zemira was a vibrant, active child, eagerly hitting her developmental milestones; calling out “mama,” climbing couches, and exploring her world with curiosity. But after a trip to the Philippines, her parents began noticing troubling changes. Zemira grew lethargic, lost her appetite, and started vomiting daily. What followed was a whirlwind of tests and an extended hospital stay that eventually confirmed the diagnosis: tuberculosis.&nbsp;&nbsp;

For her parents, the diagnosis was both shocking and terrifying. Thanks to timely intervention and months of treatment, Zemira made a full recovery. But her story underscores the fact that while Zemira was fortunate, the silent persistence of TB means countless children across the world devastated by it are not as lucky, as they continue to face delayed diagnoses and a lack of access to life-saving care.&nbsp;

From the highlands of Lesotho to the remote, rural villages of Bihar, and the underserved communities of Nigeria, Qure.ai is working hand in hand with local partners to bridge critical gaps in pediatric TB care through the power of AI.&nbsp;&nbsp;

Every one of these regions reveals a story far beyond numbers. A story of children who are often invisible in the global fight against TB. They remind us that children are not statistics; they are lives full of potential waiting to be saved. Every intervention matters, and AI can overcome geographical, social, and systemic barriers, ensuring that no child, no matter how distant or disadvantaged, is left behind.&nbsp;

The <a href="https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024" target="_blank">WHO Global TB Report 2024</a> reveals that an estimated 1.29 million children and adolescents under 15 years of age fell ill with TB, accounting for about 12% of the global TB incidence of 10.8 million cases. Even more distressing is the fact that 15% of all TB-related deaths among HIV-negative individuals in 2023 were children and young adolescents. This stark reality underscores the preventable and curable nature of TB, making these deaths not only tragic but also a grim reminder of the vulnerability of children due to systemic gaps in timely access to care.&nbsp;

While global efforts to combat TB have intensified, significant challenges persist. Nearly half of all children affected by TB remain undiagnosed and untreated, highlighting critical diagnostic and treatment gaps. The enduring global pediatric TB burden emphasizes the need for equitable and innovative solutions to address these systemic barriers and ensure every child receives the care they deserve. Today, AI healthcare solutions offer innovative approaches to address these long-standing challenges. In pediatric TB, where nonspecific symptoms and diagnostic difficulties often delay treatment, AI-driven solutions like Qure.ai’s qXR and qTrack are helping to reinforce health systems.&nbsp;

qXR is the world's most widely used AI for comprehensive chest X-ray reporting, providing pre-read assistance in &lt;1 minute with detailed lung findings. &nbsp;qTrack is an end-to-end AI-powered disease &amp; program management platform for tuberculosis through smart prompts, hardware-agnostic image viewing for AI-annotated Chest X-Rays and CTs, cross-departmental scan sharing, and custom notifications for suspect cases.&nbsp;

Qure.ai offers the only comprehensive digital solution for Pediatric TB detection and management, addressing both clinical and operational complexities with precision and reliability. Its AI-powered CXR screening supports WHO’s <a href="https://www.who.int/news/item/15-05-2023-tdr-and-who-announce-tda4child--an-operational-research-package-to-generate-data-on-treatment-decision-algorithms-for-pulmonary-tuberculosis-in-children" target="_blank">Treatment Decision Algorithm</a> (TDA) A, facilitating early detection and improved case management. This solution is WHO-evaluated* and CE MDR-certified#, ensuring they meet global safety and performance standards.&nbsp;

Built using gold standard microbiologically tested pediatric CXRs and clinically diagnosed cases, and validated through rigorous internal studies Qure.ai’s technology is finely tuned to handle the unique challenges of diagnosing TB in children. The solutions empower healthcare providers in resource-constrained settings to confidently identify and treat cases, reducing turnaround times and enabling timely interventions for high-risk groups.&nbsp;

In Africa, our pediatric TB initiative in collaboration with Partners in Health (PIH) Lesotho is strengthening health systems and improving outcomes. Qure’s AI-powered solutions have enabled screenings in Lebakeng, evaluating over 200 children since the program’s inception. These efforts are not just about numbers but about transforming lives, ensuring children previously excluded from healthcare access are now reached in the fight against TB.&nbsp;

Qure.ai is also working with Janna Health Nigeria to expand pediatric TB screenings. Operating in resource-constrained settings, these partnerships highlight the critical role of AI in closing diagnostic gaps and advancing equitable care pathways for children.&nbsp;

In the recent past, an Active Case Finding (ACF) initiative in rural India, screened over 1,100 children across 10 villages, with Qure.ai’s qXR identifying 33 presumptive TB cases. Despite logistical challenges, including villages up to 100 kilometers away, the initiative demonstrated the importance of community-based healthcare and the role of AI in addressing gaps for key and vulnerable populations.&nbsp;

Even so, the fact remains that the disparity in TB diagnosis rates is not just a healthcare challenge. It is a social justice issue. The WHO <a href="https://www.who.int/news/item/20-11-2024-inclusion-for-every-child--reaching-every-child-affected-by-tuberculosis" target="_blank">reported</a> that only 42% of eligible household contacts aged under five received TB preventive care, reflecting inequities in service delivery. AI-powered solutions like qXR and qTrack offer scalable, cost-effective solutions that aligns with global priorities:&nbsp;

•	Strengthening Health Systems: By supporting healthcare workers with AI-driven insights, even non-specialists in remote areas can diagnose TB with confidence.&nbsp;

•	Focusing on Key and Vulnerable Populations: AI identifies high-risk groups, such as children under five or those living in TB-affected households, enabling targeted interventions.&nbsp;

•	Bridging Policy-Practice Gaps: AI complements WHO’s updated Roadmap toward ending TB in children, offering practical solutions to address persistent inequities.&nbsp;

Ending TB in children requires a unified effort, including policy support to secure funding for AI driven solutions, training healthcare workers to effectively use AI technologies, and scaling innovations to ensure that no region or community is left behind.&nbsp;

The effort against pediatric TB is as much about inclusion as innovation. AI has the power to bridge care gaps, strengthen health systems, and ensure every child can receive timely, effective TB care. The question remains: are we ready to harness this potential and create a world where no child’s future is stolen by TB?&nbsp;

large_Harnessing AI to Combat Pediatric TB-02.png

medium_Harnessing AI to Combat Pediatric TB-02.png

small_Harnessing AI to Combat Pediatric TB-02.png

thumbnail_Harnessing AI to Combat Pediatric TB-02.png

Harnessing AI to Combat Pediatric TB-02.png

Fighting Child Mortality: Is AI the Missing Link?

Stroke care has always been both my passion and my purpose. Over decades of refining my expertise in neurosurgery, ranging from conventional to advanced microneurosurgery and interventional techniques, I’ve witnessed the evolution of treatments and technologies firsthand. From performing over 10,000 neurosurgeries and 2,000 endovascular procedures to mentoring younger stroke teams, the journey has been as challenging as it has been fulfilling.&nbsp;

Despite advancements, the reality of stroke care in India remains sobering. Stroke affects approximately 1.8 million people in India annually, with an incidence rate of 105–152 per 100,000 individuals per year. The burden is even heavier in rural and underserved regions, where access to timely, specialized care is limited. Neurology itself is a challenging field, with fewer than one neurologist available per 100,000 people across the country (<a href="https://stroke-india.org/" target="_blank">Indian Stroke Association</a>, <a href="https://journals.sagepub.com/" target="_blank">SAGE Journals</a>). This gap highlights the pressing need for innovative solutions to bridge the disparity in stroke care.

Connecting the Dots: The Hub-and-Spoke Model &nbsp;

Insights onArtificial Intelligence &Healthcare Technology

Insights on
Artificial Intelligence &
Healthcare Technology